After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.
You may also be interested in...
After Canceling IPO, Radius May Tap Institutional Investors
With its IPO withdrawn, osteoporosis drug developer Radius Therapeutics is likely to seek funding from institutional backers. The company has just enough cash to last it through the first quarter, with big costs for a Phase III trial in the works.
Zelos Becoms Azelon; Restructures To Close A Series A
The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.
Zelos Becoms Azelon; Restructures To Close A Series A
The osteoporosis drug company has revamped its focus and brought in new investors as it pushes forward with its nasal spray for osteoporosis.